الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 16 |  |  |
| | | from | 16 | | |
Abstract
A new series of novel pyrimidine derivatives (2-30) were obtained from propylthiouracil (1) and evaluated for anticancer activity. The newly synthesized compounds were characterized by IR, 1H NMR, 13C NMR, MS and elemental micro analysis. Eight of the synthesized compounds were selected and tested by National Cancer Institute (NCI), USA, for anticancer activity against 60 different human tumour cell lines. Among the compounds tested, 2-(3,5-dimethyl-1H-pyrazol-1-yl)- 6-propyl-3,4-dihydropyrimidin-4-one (26) (NSC 771835) was found to be the most active candidate of the series at five dose level screening with no selectivity towards any cell panels. (i.e. general anticancer).